By enhancing insulin secretion, inhibiting glucagon release, delaying gastric emptying, and suppressing appetite, GLP-1R agonists (GLP-1RAs) have demonstrated efficacy in managing type 2 diabetes and obesity (23). This evidence concerns the gene GLP1R and type 2 diabetes mellitus.